Inspire Medical Systems, Inc. Research and Development Expense
Inspire Medical Systems, Inc. (INSP) reported Research and Development Expense of $24.70 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-03
- Inspire Medical Systems, Inc. research and development expense for the quarter ending 2026-06-30 was $24.70M, a 5.77% decline year-over-year.
- Inspire Medical Systems, Inc. research and development expense for the quarter ending 2026-03-31 was $25.83M, a 7.11% decline year-over-year.
- Inspire Medical Systems, Inc. research and development expense for the quarter ending 2025-12-31 was $24.94M, a 17.78% decline year-over-year.
- Inspire Medical Systems, Inc. research and development expense for the quarter ending 2025-09-30 was $24.21M, a 7.18% decline year-over-year.
- Inspire Medical Systems, Inc. research and development expense for fiscal 2025 was $103.17M, a 9.61% decline from fiscal 2024.
- Inspire Medical Systems, Inc. research and development expense for fiscal 2024 was $114.13M, a 2.07% decline from fiscal 2023.
- Inspire Medical Systems, Inc. research and development expense for fiscal 2023 was $116.54M, a 69.77% increase from fiscal 2022.
- Inspire Medical Systems, Inc. research and development expense for fiscal 2022 was $68.64M, a 83.79% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $24.70M 10-Q · filed 2026-08-03 | $50.52M 10-Q · filed 2026-08-03 | $75.47M derived: sum of 3 quarters · filed 2026-08-03 | $99.68M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $25.83M 10-Q · filed 2026-05-04 | $50.77M derived: sum of 2 quarters · filed 2026-05-04 | $74.98M derived: sum of 3 quarters · filed 2026-05-04 | $101.19M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $24.94M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $49.15M derived: sum of 2 quarters · filed 2026-02-13 | $75.36M derived: sum of 3 quarters · filed 2026-08-03 | $103.17M 10-K · filed 2026-02-13 |
| 2025-09-30 | $24.21M 10-Q · filed 2025-11-03 | $50.42M derived: sum of 2 quarters · filed 2026-08-03 | $78.22M 10-Q · filed 2025-11-03 | $108.56M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $26.21M 10-Q · filed 2026-08-03 | $54.01M 10-Q · filed 2026-08-03 | $84.35M derived: sum of 3 quarters · filed 2026-08-03 | $110.43M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $27.80M 10-Q · filed 2026-05-04 | $58.14M derived: sum of 2 quarters · filed 2026-05-04 | $84.22M derived: sum of 3 quarters · filed 2026-05-04 | $113.08M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $30.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $56.42M derived: sum of 2 quarters · filed 2026-02-13 | $85.28M derived: sum of 3 quarters · filed 2026-02-13 | $114.13M 10-K · filed 2026-02-13 |
| 2024-09-30 | $26.08M 10-Q · filed 2025-11-03 | $54.94M derived: sum of 2 quarters · filed 2025-11-03 | $83.79M 10-Q · filed 2025-11-03 | $114.84M derived: sum of 4 quarters · filed 2026-02-13 |
| 2024-06-30 | $28.86M 10-Q · filed 2025-08-04 | $57.71M 10-Q · filed 2025-08-04 | $88.76M derived: sum of 3 quarters · filed 2026-02-13 | $117.91M derived: sum of 4 quarters · filed 2026-02-13 |
| 2024-03-31 | $28.85M 10-Q · filed 2025-05-05 | $59.90M derived: sum of 2 quarters · filed 2026-02-13 | $89.05M derived: sum of 3 quarters · filed 2026-02-13 | $119.87M derived: sum of 4 quarters · filed 2026-02-13 |
| 2023-12-31 | $31.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $60.20M derived: sum of 2 quarters · filed 2026-02-13 | $91.02M derived: sum of 3 quarters · filed 2026-02-13 | $116.54M 10-K · filed 2026-02-13 |
| 2023-09-30 | $29.14M 10-Q · filed 2024-11-04 | $59.97M derived: sum of 2 quarters · filed 2024-11-04 | $85.48M 10-Q · filed 2024-11-04 | $106.73M derived: sum of 4 quarters · filed 2025-02-10 |
| 2023-06-30 | $30.82M 10-Q · filed 2024-08-06 | $56.34M 10-Q · filed 2024-08-06 | $77.59M derived: sum of 3 quarters · filed 2025-02-10 | $98.58M derived: sum of 4 quarters · filed 2025-02-10 |
| 2023-03-31 | $25.52M 10-Q · filed 2024-05-07 | $46.77M derived: sum of 2 quarters · filed 2025-02-10 | $67.76M derived: sum of 3 quarters · filed 2025-02-10 | $82.29M derived: sum of 4 quarters · filed 2025-02-10 |
| 2022-12-31 | $21.25M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-10 | $42.24M derived: sum of 2 quarters · filed 2025-02-10 | $56.77M derived: sum of 3 quarters · filed 2025-02-10 | $68.64M 10-K · filed 2025-02-10 |
| 2022-09-30 | $20.99M 10-Q · filed 2023-11-07 | $35.53M derived: sum of 2 quarters · filed 2023-11-07 | $47.40M 10-Q · filed 2023-11-07 | $57.69M derived: sum of 4 quarters · filed 2024-02-09 |
| 2022-06-30 | $14.53M 10-Q · filed 2023-08-01 | $26.40M 10-Q · filed 2023-08-01 | $36.70M derived: sum of 3 quarters · filed 2024-02-09 | $46.31M derived: sum of 4 quarters · filed 2024-02-09 |
| 2022-03-31 | $11.87M 10-Q · filed 2023-05-02 | $22.16M derived: sum of 2 quarters · filed 2024-02-09 | $31.78M derived: sum of 3 quarters · filed 2024-02-09 | $41.07M derived: sum of 4 quarters · filed 2024-02-09 |
| 2021-12-31 | $10.29M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-09 | $19.91M derived: sum of 2 quarters · filed 2024-02-09 | $29.20M derived: sum of 3 quarters · filed 2024-02-09 | $37.35M 10-K · filed 2024-02-09 |
| 2021-09-30 | $9.61M 10-Q · filed 2022-11-01 | $18.90M derived: sum of 2 quarters · filed 2022-11-01 | $27.06M 10-Q · filed 2022-11-01 | $34.34M derived: sum of 4 quarters · filed 2023-02-10 |
| 2021-06-30 | $9.29M 10-Q · filed 2022-08-02 | $17.44M 10-Q · filed 2022-08-02 | $24.73M derived: sum of 3 quarters · filed 2023-02-10 | $32.03M derived: sum of 4 quarters · filed 2023-02-10 |
| 2021-03-31 | $8.15M 10-Q · filed 2022-05-03 | $15.44M derived: sum of 2 quarters · filed 2023-02-10 | $22.75M derived: sum of 3 quarters · filed 2023-02-10 | $28.81M derived: sum of 4 quarters · filed 2023-02-10 |
| 2020-12-31 | $7.29M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-10 | $14.59M derived: sum of 2 quarters · filed 2023-02-10 | $20.65M derived: sum of 3 quarters · filed 2023-02-10 | $26.09M 10-K · filed 2023-02-10 |
| 2020-09-30 | $7.31M 10-Q · filed 2021-11-02 | $13.37M derived: sum of 2 quarters · filed 2021-11-02 | $18.81M 10-Q · filed 2021-11-02 | $22.57M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-06-30 | $6.06M 10-Q · filed 2021-08-03 | $11.50M 10-Q · filed 2021-08-03 | $15.27M derived: sum of 3 quarters · filed 2022-02-15 | $18.89M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-03-31 | $5.44M 10-Q · filed 2021-05-04 | $9.21M derived: sum of 2 quarters · filed 2022-02-15 | $12.83M derived: sum of 3 quarters · filed 2022-02-15 | $15.67M derived: sum of 4 quarters · filed 2022-02-15 |
| 2019-12-31 | $3.77M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $7.39M derived: sum of 2 quarters · filed 2022-02-15 | $10.24M derived: sum of 3 quarters · filed 2022-02-15 | $12.84M 10-K · filed 2022-02-15 |
| 2019-09-30 | $3.62M 10-Q · filed 2020-11-02 | $6.47M derived: sum of 2 quarters · filed 2020-11-02 | $9.07M 10-Q · filed 2020-11-02 | $11.22M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-06-30 | $2.85M 10-Q · filed 2020-08-04 | $5.45M 10-Q · filed 2020-08-04 | $7.60M derived: sum of 3 quarters · filed 2021-02-24 | $9.37M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-03-31 | $2.60M 10-Q · filed 2020-05-05 | $4.75M derived: sum of 2 quarters · filed 2021-02-24 | $6.53M derived: sum of 3 quarters · filed 2021-02-24 | $8.26M derived: sum of 4 quarters · filed 2021-02-24 |
| 2018-12-31 | $2.15M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $3.92M derived: sum of 2 quarters · filed 2021-02-24 | $5.66M derived: sum of 3 quarters · filed 2021-02-24 | $7.39M 10-K · filed 2021-02-24 |
| 2018-09-30 | $1.77M 10-Q · filed 2019-11-05 | $3.51M derived: sum of 2 quarters · filed 2019-11-05 | $5.24M 10-Q · filed 2019-11-05 | $6.92M derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-06-30 | $1.74M 10-Q · filed 2019-08-06 | $3.46M 10-Q · filed 2019-08-06 | $5.15M derived: sum of 3 quarters · filed 2020-02-25 | $6.32M derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-03-31 | $1.73M 10-Q · filed 2019-05-07 | $3.41M derived: sum of 2 quarters · filed 2020-02-25 | $4.59M derived: sum of 3 quarters · filed 2020-02-25 | $6.33M derived: sum of 4 quarters · filed 2020-02-25 |
| 2017-12-31 | $1.68M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $2.86M derived: sum of 2 quarters · filed 2020-02-25 | $4.60M derived: sum of 3 quarters · filed 2020-02-25 | $6.19M 10-K · filed 2020-02-25 |
| 2017-09-30 | $1.18M 10-Q · filed 2018-11-06 | $2.92M derived: sum of 2 quarters · filed 2018-11-06 | $4.51M 10-Q · filed 2018-11-06 | |
| 2017-06-30 | $1.74M 10-Q · filed 2018-08-07 | $3.34M 10-Q · filed 2018-08-07 | ||
| 2017-03-31 | $1.59M 10-Q · filed 2018-06-07 | |||
| 2016-12-31 | $7.09M 10-K · filed 2019-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NovoCure Ltd (NVCR) | $1.886B | -11.87 | |
| LEMAITRE VASCULAR INC (LMAT) | United States | $1.848B | 33.37 |
| UFP TECHNOLOGIES INC (UFPT) | United States | $2.308B | 28.37 |
| KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) | United States | $1.535B | -9.02 |
| Alphatec Holdings, Inc. (ATEC) | United States | $1.531B | -12.14 |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| PROCEPT BioRobotics Corp (PRCT) | United States | $1.001B | -11.77 |